IMUX
Immunic Inc
Halal Rating :
Last Price
$0.99
Last updated:
Market Cap
-
7D Change
-7.49%
1 Year Change
-14.29%
Company Overview
Industries
Exchange
Next Earnings Date
Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies. The company's primary focus is on treating chronic inflammatory and autoimmune diseases. Their lead program, IMU-838 (vidofludimus calcium), is in development for multiple sclerosis and other chronic inflammatory diseases.
The company is currently in research and development phase, with multiple drug candidates in various stages of clinical trials. They do not yet have any commercialized products or revenue-generating operations.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Immunic Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.